James Lukas Laws

James Lukas Laws

Auto-generated profile, based on publicly available information

James Lukas Laws

Vanderbilt University Medical Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
JLJ. Lukas Laws
J. Lukas Laws
MLMegan C. Lancaster
Megan C. Lancaster
MSM. Ben Shoemaker
M. Ben Shoemaker
WSWilliam G. Stevenson
William G. Stevenson
RHRebecca R. Hung
Rebecca R. Hung
LSLynne W. Stevenson
Lynne W. Stevenson
There is increasing evidence regarding the prevalence of genetic cardiomyopathies, for which arrhythmias may be the first presentation. Ventricular and atrial arrhythmias presenting in the absence of known myocardial disease are often labelled as idiopathic, or lone. While ventricular arrhythmias are well-recognized as presentation for arrhythmogenic cardiomyopathy in the right ventricle, the scope of arrhythmogenic cardiomyopathy has broadened to include those with dominant left ventricular involvement, usually with a phenotype of dilated cardiomyopathy. In addition, careful evaluation for genetic cardiomyopathy is also warranted for patients presenting with frequent premature ventricular contractions, conduction system disease, and early onset atrial fibrillation, in which most detected genes are in the cardiomyopathy panels. Sudden death can occur early in the course of these genetic cardiomyopathies, for which risk is not adequately tracked by left ventricular ejection fraction. Only a few of the cardiomyopathy genotypes implicated in early sudden death are recognized in current indications for implantable cardioverter defibrillators which otherwise rely upon a left ventricular ejection fraction ≤0.35 in dilated cardiomyopathy. The genetic diagnoses impact other aspects of clinical management such as exercise prescription and pharmacological therapy of arrhythmias, and new therapies are coming into clinical investigation for specific genetic cardiomyopathies. The expansion of available genetic information and implications raises new challenges for genetic counseling, particularly with the family member who has no evidence of a cardiomyopathy phenotype and may face a potentially negative impact of a genetic diagnosis. Discussions of risk for both probands and relatives need to be tailored to their numeric literacy during shared decision-making. For patients presenting with arrhythmias or cardiomyopathy, extension of genetic testing and its implications will enable cascade screening, intervention to change the trajectory for specific genotype-phenotype profiles, and enable further development and evaluation of emerging targeted therapies.

30 October 2025 in European Heart Journal
Verified
Journal Article
Open access
JLJ Lukas Laws
J Lukas Laws
MSMahsima Shabani
Mahsima Shabani
HWHollie L Williams
Hollie L Williams
DGDakota D Grauherr
Dakota D Grauherr
WKWendy M Kilbourne
Wendy M Kilbourne
MSM Benjamin Shoemaker
M Benjamin Shoemaker
Background and Aims: Genetic testing is recommended for select patients with atrial fibrillation (AF). The aims of this study were to define the results of genetic evaluation and its therapeutic impact for patients referred to a dedicated AF precision medicine clinic. Methods: Patients diagnosed with AF before age 60 were candidates for referral. In addition to standard evaluation with history, physical exam, and electrocardiogram (ECG), genetic evaluation included a three-generation pedigree, cardiac imaging, ambulatory monitoring, and clinical genetic testing with a cardiomyopathy/arrhythmia panel. Results: Overall, 264 participants were referred: the median age was 47 years (Q1, Q3: 38, 55), 77 (29%) were female, and 236 (89%) were White. Median age at AF diagnosis was 39 years (Q1, Q3: 31, 48), and median time from AF diagnosis to evaluation was 3.7 years (Q1, Q3: 0.9, 10). A total of 242 patients (92%) underwent genetic testing, which identified a pathogenic or likely pathogenic variant in 48 (20%). The strongest predictors of positive genetic testing were history of cardiomyopathy, infranodal conduction disease, and elevated T1 or late gadolinium enhancement on cardiac magnetic resonance imaging (all P < .05). The strongest predictors of negative genetic testing were obstructive sleep apnoea and a normal 12-lead ECG (both P < .04). Overall, genetic testing changed clinical management in 52% of patients with positive genetic testing, highlighted by seven new implantable cardioverter-defibrillator placements and initiation of disease-modifying therapy in 16 patients. Conclusions: Genetic testing was positive in 20% of patients with early-onset AF referred to a dedicated AF precision medicine clinic. Genetic testing results may change clinical management in genotype-positive patients.

17 March 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
BLBruno Bezerra Lima
Bruno Bezerra Lima
TDTam T Doan
Tam T Doan
AFAttila Feher
Attila Feher
JWJames C. Wilkinson
James C. Wilkinson
MKMarvin W. Kronenberg
Marvin W. Kronenberg
JSJonathan Soslow
Jonathan Soslow
Heart transplantation significantly enhances survival and quality of life for patients with end‐stage heart failure. Despite advances in surgical and postoperative care, immune‐mediated complications, acute graft rejection and cardiac allograft vasculopathy (CAV), remain major barriers to long‐term success. Acute rejection predominantly affects early posttransplant survival, whereas CAV becomes a leading cause of mortality in later years. The gold standards for diagnosis, endomyocardial biopsy for rejection and coronary angiography for CAV, are invasive and imperfect. Noninvasive multimodality imaging is increasingly used to complement or, in selected scenarios, defer invasive testing. Echocardiography with strain detects early myocardial dysfunction when ejection fraction is preserved; stress echocardiography provides prognostic information for CAV. Quantitative techniques, positron emission tomography myocardial blood flow/myocardial flow reserve and quantitative cardiac magnetic resonance perfusion, improve detection of diffuse, stage‐dependent CAV compared with qualitative assessments. Cardiac magnetic resonance tissue mapping characterizes edema and fibrosis relevant to rejection surveillance; fluorodeoxyglucose‐positron emission tomography for inflammation is emerging but remains investigational in most centers. Cardiac computed tomography angiography defines coronary anatomy and plaque with excellent negative predictive value and offers physiologic assessment with computed tomography‐myocardial perfusion imaging/computed tomography‐derived fractional flow reserve; it is best used strategically rather than as an annually repeated test. This contemporary review synthesizes the strengths, limitations, and practical roles of echocardiography, nuclear imaging, cardiac magnetic resonance, and cardiac computed tomography angiography across adult and pediatric populations; highlights areas where quantitative methods add incremental value; and provides pragmatic, stage‐aware surveillance frameworks. Integrating modalities can reduce reliance on invasive procedures, lower procedural risk, and refine therapeutic decision‐making benefits that are particularly relevant for children and other patients for whom repeated invasive testing is undesirable.

12 May 2023 in Circulation Research
Verified
Journal Article
Closed access
SHS. Neil Holby
S. Neil Holby
TRTadarro Lee Richardson
Tadarro Lee Richardson
JLJ. Lukas Laws
J. Lukas Laws
TMThomas A. McLaren
Thomas A. McLaren
JSJonathan H. Soslow
Jonathan H. Soslow
SHSean G. Hughes
Sean G. Hughes
Infection with SARS-CoV-2, the virus that causes COVID, is associated with numerous potential secondary complications. Global efforts have been dedicated to understanding the myriad potential cardiovascular sequelae which may occur during acute infection, convalescence, or recovery. Because patients often present with nonspecific symptoms and laboratory findings, cardiac imaging has emerged as an important tool for the discrimination of pulmonary and cardiovascular complications of this disease. The clinician investigating a potential COVID-related complication must account not only for the relative utility of various cardiac imaging modalities but also for the risk of infectious exposure to staff and other patients. Extraordinary clinical and scholarly efforts have brought the international medical community closer to a consensus on the appropriate indications for diagnostic cardiac imaging during this protracted pandemic. In this review, we summarize the existing literature and reference major societal guidelines to provide an overview of the indications and utility of echocardiography, nuclear imaging, cardiac computed tomography, and cardiac magnetic resonance imaging for the diagnosis of cardiovascular complications of COVID.

24 December 2021 in Case Reports in Cardiology
Verified
Journal Article
Open access
PDF file
JLJames L. Laws
James L. Laws
EKEsther Kim
Esther Kim
RHRebecca Hung
Rebecca Hung
JLJoAnn Lindenfeld
JoAnn Lindenfeld
RGRicha Gupta
Richa Gupta
Drug-induced myocarditis is a rare, but underrecognized complication of clozapine therapy for schizophrenia. We present a case of clozapine-induced myocarditis with recovery of cardiac function after drug cessation and summarize the literature to highlight the variable presentation of this condition.

1 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JDJonathan Michael Daw
Jonathan Michael Daw
HWHollie L. Williams
Hollie L. Williams
CPCassady J. Pelphrey
Cassady J. Pelphrey
DGDakota D. Grauherr
Dakota D. Grauherr
DCDiane M. Crawford
Diane M. Crawford
JLJames Lukas Laws
James Lukas Laws
Background: Genetic testing is now recommended for select patients with early-onset atrial fibrillation (AF). Hemochromatosis is an autosomal recessive syndrome that occurs in patients who carry two pathogenic or likely-pathogenic (P/LP) variants in HFE. HFE is included on some genetic testing panels used for patients with AF. Hemochromatosis causes cardiomyopathy due to iron overload in the ventricle; however, it is unknown whether AF can be an early manifestation that is identified by genetic testing. Methods: A total of 347 patients were referred to a dedicated AF precision medicine clinic. The clinical diagnostic evaluation included an H&P, 12-lead ECG, ambulatory ECG monitoring, and cardiac imaging (cardiac MRI and/or TTE). Genetic testing was performed using CLIA-approved laboratories: Labcorp/Invitae, GeneDx, or Vanderbilt University Medical Center. HFE was included on the cardiomyopathy panel used by 2 of the 3 laboratories. Results: HFE was tested in 165 participants (median age 46 years [IQR 35-55], 115 [70%] male, 149 [90%] White). Six participants (4%) had two pathogenic variants in HFE. All of them were C282Y/H63D compound heterozygotes. Forty-one participants (25%) were heterozygous carriers of one pathogenic HFE variant. Among the 6 participants with 2 pathogenic HFE variants, the median ferritin level was 346 mcg/L [IQR 262, 496] (normal <300 mcg/L males, 11.4 ms; liver iron concentration 3.4 mg/g, normal <2 mg/g). Three out of 6 participants were referred for a hematology evaluation and 2 out of 6 were started on therapeutic phlebotomy. Conclusion: Genetic testing can identify patients with early-onset AF who are genetically susceptible to hemochromatosis, have evidence of iron overload, and receive early intervention with therapeutic phlebotomy. These results suggest HFE should be sequenced as part of genetic testing for early-onset AF, but larger sample sizes are needed to confirm these results.